The Role of Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Staging and Treatment of Melanoma

Clinics in Plastic Surgery

Volumn 37, Issue 1, 2010, Pages 79-99

  Stadelmann, Wayne K ^a  

^a Stadelmann Center for Plastic Surgery   (United States)

Author keywords

Biopsy; Lymphoscintigram; Melanoma; Sentinel lymph node; Staging

Indexed keywords

ALPHA2B INTERFERON; ISOSULFAN BLUE; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M;

CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEMATOMA; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPHADENECTOMY; LYMPHATIC DRAINAGE; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; MELANOMA; MORBIDITY; PAIN; PATIENT SAFETY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SENSORY DYSFUNCTION; SENTINEL LYMPH NODE BIOPSY; STANDARDIZATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

COLORING AGENTS; GAMMAPROTEOBACTERIA; HUMANS; INTRAOPERATIVE PERIOD; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 70449380293     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2009.08.001     Document Type: Review

References (107)

1. Lens M.B., and Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150 (2004) 179-185
2. National Cancer Institute. Cancer stat fact sheets. Available at: (2008). www.seer.cancer.gov/statfacts
3. Veronesi U., and Cascinelli N. Narrow excision (1 cm margins). A safe procedure for thin cutaneous melanoma. Arch Surg 126 (1991) 438-441
4. Balch C.M., Urist M.M., Karakousis C.P., et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg 218 (1993) 262-269
5. Heaton K.M., Sussman J.J., Gershenwald J.E., et al. Surgical margins and prognostic factors in patients with thick (>4.0 mm) primary melanoma. Ann Surg Oncol 5 (1998) 322-328
6. Kenady D.E., Brown B.W., and McBride C.M. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery 92 (1992) 615-618
7. Morton D.L., Wen D.-R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
8. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
9. Balch C.M., Buzaid A.C., Soong S.-J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
10. Balch C.M. Cutaneous melanoma. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th edition (2002), Springer Verlag, New York 209-217
11. Balch C.M., Soong S.-J., Atkins M.B., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54 (2004) 131-149
12. Doubrovsky A., de Wilt J.H.W., Scolyer R.S., et al. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 11 (2004) 829-836
13. Stadelmann W.K., Rapaport D.P., Soong S.J., et al. Prognostic. Clinical and pathologic features. In: Balch C.M. (Ed). Cutaneous melanoma. 3rd edition (1998), Quality Medical Publishing, St Louis (MO) 11-35
14. Soong S.J. A computerized mathematical model and scoring system for predicting outcome in patients with localized melanoma. In: Balch C.M., Houghton A.N., Milton G.W., et al. (Eds). Cutaneous melanoma. 2nd edition (1992), JB Lippincott, Philadelphia 200
15. Stadelmann W.K., and Reintgen D.S. Prognosis in malignant melanoma. Hematol Oncol Clin North Am 12 (1998) 767-796
16. Reintgen D.S., Rapaport D.P., Tanabe K.K., et al. Lymphatic mapping and sentinel lymphadenectomy. In: Balch C.M. (Ed). Cutaneous melanoma. 3rd edition (1998), Quality Medical Publishing, St Louis (MO) 227-244
17. Starz H., Siedlecki K., and Balda B.-R. Sentinel lymphadenectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11 (2004) 162S-168S
18. Seaman W., and Powers W. Studies on the distribution of radioactive colloidal gold in regional lymph nodes containing cancer. Cancer 8 (1955) 1044-1046
19. Gould E.A., Winship T., Pholbin P.H., et al. Observations on a "sentinel node" in cancer of the parotid. Cancer 13 (1960) 77-78
20. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer 39 (1977) 456-466
21. Thompson J.F., Stretch J.R., Uren R.F., et al. Sentinel node biopsy for melanoma: where have we been and where are we going. Ann Surg Oncol 11 (2004) 147S-151S
22. Reintgen D.S., Cruse C.W., Wells K.E., et al. The orderly progression of melanoma nodal metastases. Ann Surg 220 6 (1994) 759-767
23. Thompson J.F., McCarthy W.H., Bosch C.M., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5 (1995) 255-260
24. Reintgen D.S., Albertini J., Miliotes G., et al. The accurate staging and modern day treatment of malignant melanoma. Cancer Res Ther Control 4 (1995) 183-197
25. Stadelmann W.K., Javaheri S., Cruse C.W., et al. The use of sentinel lymph-adenectomy in squamous cell carcinoma of the wrist. A case report. J Hand Surg Am 22 (1997) 726-731
26. Javaheri S., Cruse C.W., Stadelmann W.K., et al. Sentinel node excision for the diagnosis of metastatic neuroendocrine carcinoma of the skin: a case report. Ann Plast Surg 39 (1997) 299-302
27. Leong S.P.L. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 11 (2004) 192S-197S
28. Saha S., Dan A.G., Berman B., et al. Lymphazurin 1% versus 99mTc sulfur colloid for lymphatic mapping in colorectal tumors: a comparative analysis. Ann Surg Oncol 11 (2004) 21-26
29. Kitajima M., and Kitagawa Y. Universal applications of sentinel node technology. Ann Surg Oncol 11 (2004) 144S-146S
30. Scolyer R.A., Thompson J.F., Li L.-X.L., et al. Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol 11 (2004) 174S-178S
31. Crowley N.J., and Seigler H.F. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 66 (1990) 2522-2527
32. Balch C.M., Soong S.J., Bartolucci A.A., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224 (1996) 255
33. Sim F.H., Taylor W.F., Ivins J.C., et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 41 (1978) 948
34. Veronesi U., Adamus J., Bandiera D.C., et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49 (1982) 2420-2430
35. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial-WHO Melanoma Programme. Lancet 351 (1998) 793-796
36. Pawlik T.M., and Gershenwald J.E. Sentinel node biopsy for melanoma. Contemp Surg 61 4 (2005) 175-182
37. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7 (2000) 87-97
38. Balch C.M., Soong S.J., Gershenwald J., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the new American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
39. Dessureault S., Soong S.J., Ross M.I., et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1.0 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8 (2001) 749-751
40. Pawlik T.M., Ross M.I., and Gershenwald J.E. Lymphatic mapping in the molecular era. Ann Surg Oncol 11 (2004) 362-374
41. Sappey M.P.C. Anatomie, physiologie, pathologie, des vaisseaux lymphatiques considérés chez l'homme et les vertègres (1864), A. Delahaye & E. Lecrosnier, Paris (France)
42. Sherman A.I., and Ter-Pogossian M. Lymph node concentration of radioactive colloidal gold following interstitial injection. Cancer 6 (1953) 1238-1240
43. 99mTc-sulfur colloid. Radiology 92 (1969) 1369
44. Meyer C.W., Lecklitner M.L., Logic J.R., et al. Technetium-99m sulfur-colloid cutaneous lymphoscintigraphy in the management of truncal melanoma. Radiology 131 (1979) 205-209
45. Ali-Salaam P., and Ariyan S. Lymphatic mapping and sentinel lymph node biopsies. Clin Plast Surg 27 (2000) 421-429
46. McMasters K.M., Chao C., Wong S.L., et al. Interval sentinel lymph nodes in melanoma. Arch Surg 137 (2002) 543-547 [discussion: 7-9]
47. Uren R.F. Lymphatic drainage of the skin. Ann Surg Oncol 11 (2004) 179S-185S
48. Momeni R., and Ariyan S. Pulse oximetry declines do to intradermal isosulfan blue dye: a controlled prospective study. Ann Surg Oncol 11 4 (2004) 434-437
49. Cimmino V.M., Brown A.C., Szocik J.F., et al. Allergic reactions to isosulfan blue during sentinel node biopsy-a common event. Surgery 130 (2001) 439-442
50. Komenaka I.K., Bauer V.P., Schnabel F.R., et al. Allergic reactions to isosulfan blue dye in sentinel lymph node mapping. Breast J 11 (2005) 70-72
51. Raut C.P., Hunt K.K., Akins J.S., et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis. Cancer 104 (2005) 692-699 published online
52. Montgomery L.L., Thorne A.C., Van Zee K.J., et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 95 (2002) 385-388
53. Alex J.C., Weaver D.L., Fairbank J.T., et al. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2 (1993) 303-308
54. Krag D.N., Meijer S.J., Weaver D.L., et al. Minimal-access surgery for staging of melanoma. Arch Surg 130 (1995) 654
55. Van der Veen H., Hoekstra O.S., Paul M.A., et al. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 81 (1994) 1769-1770
56. Gershenwald J.E., Tseng C.-H., Thompson W., et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124 (1998) 203-210
57. Albertini J.J., Cruse C.W., Rapaport D., et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 223 (1996) 217-224
58. Koopal S.A., Tiebosch A.T., Albertus P.D., et al. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer 89 (2000) 1720-1725
59. Cochran A.J., Wen D.R., and Morton D.L. Occult tumor cells in the lymph nodes of patients with pathologic stage I malignant melanoma: an immunohistochemical study. Am J Surg Pathol 12 (1988) 612-618 Bedrosian
60. Ferrone C.R., Panagaes K.S., Busam K., et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 9 (2002) 637-645
61. Essner R., Chung M.H., Bleicher R., et al. Prognostic implications of thick (≥4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 9 (2001) 754-761
62. Bleicher R.J., Essner R., Foshag L.J., et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanoma. J Clin Oncol 21 (2003) 1326-1331
63. Wong S.L., Brady M.S., Busam K.J., et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13 (2006) 302-309
64. Sondak V., Taylor J.M.G., Sabel M.S., et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11 (2004) 247-258
65. Bedrosian I., Faries M.B., Guerry IV D., et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 7 (2000) 262-267
66. Ranieri J.M., Wagner J.D., Wenck S., et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 3 (2006) 927-932
67. Chao C., Martin R.C.G., Ross M.I., et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 11 (2004) 259-264
68. Stitzenberg K.B., Groben P.A., Stern S., et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma Breslow thickness ≤1.0 mm. Ann Surg Oncol 11 (2004) 900-906
69. Wrightson WR, Reintgen DS, Edwards MJ, et al. Morbidity of sentinel lymph node biopsy for melanoma. Annual Meeting of the Society of Surgical Oncology, Washington, DC, March 15-18, 2001 [abstr 28].
70. Wrightson W.R., Wong S.L., Edwards M.J., et al. Sunbelt Melanoma Trial Study Group. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 10 (2003) 676-680
71. McMasters K.M., Reintgen D.S., Ross M.I., et al. Sentinel node biopsy for melanoma controversy despite widespread agreement. J Clin Oncol 11 (2001) 2851-2855
72. World Health Organization declares lymphatic mapping to be the standard of care for melanoma. Oncology 13 (1999) 288
73. Medalie N.S., and Ackerman B. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis. Part I. Am J Dermatopathol 25 (2003) 399-417
74. Medalie N.S., and Ackerman B. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis. Part II. Am J Dermatopathol 25 (2003) 473-484
75. McMasters K.M. Editorial. What good is sentinel lymph node biopsy for melanoma if it does not improve survival?. Ann Surg Oncol 11 9 (2004) 810-812
76. Morton D.L. Sentinel node mapping and an international sentinel node society: current issues and future directions. Ann Surg Oncol 11 (2004) 137S-143S
77. Nieweg O.E., and Estourgie S.E. What is a sentinel node and what is a false-negative sentinel node?. Ann Surg Oncol 3 (2004) 169S-173S
78. McMasters K.M., Reintgen D.S., Ross M.I., et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol 8 (2001) 192-197
79. Abou-Nukta F., and Ariyan S. Sentinel lymph node biopsies in melanoma: how many nodes do we really need?. Ann Plast Surg 60 (2008) 416-419
80. Martin R.C., Fey J., Yeung H., et al. Highest isotope count does not predict sentinel node positivity in all breast cancer patients. Ann Surg Oncol 8 (2001) 592-597
81. Norman J., Cruse C.W., Espinosa C., et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 162 (1991) 432-437
82. Wells K.E., Cruse C.W., Daniels S., et al. The use of lymphoscintigraphy in melanoma of the head and neck. Plast Reconstr Surg 93 (1994) 757-761
83. Chao C., Wong S.L., Edwards M.J., et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol 10 1 (2003) 21-26
84. Berman C.G., Norman J., Cruse C.W., et al. Lymphscintigraphy in malignant melanoma. Ann Plast Surg 28 (1992) 29-32
85. Stadelmann W.K., Cobbins L., and Lentsch E.J. Incidence of nonlocalization of sentinel lymph nodes using preoperative lymphoscintigraphy in 74 consecutive head and neck melanoma and Merkel cell carcinoma patients. Ann Plast Surg 52 (2004) 546-550
86. Medina-Franco H., Beenken S.W., Heslin M.J., et al. Sentinel node biopsy for cutaneous melanoma in the head and neck. Ann Surg Oncol 8 (2001) 716-719
87. MacNeill K.N., Ghazarian D., McCready D., et al. Sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Ann Surg Oncol 12 (2005) 726-732
88. Trotti A., and Peters L.J. The role of radiotherapy in the primary management of cutaneous melanoma. Ann Plast Surg 28 (1992) 39-44
89. O'Brien C.J., Petersen-Schaefer K., Papadopoulos T., et al. Evaluation of 107 therapeutic and elective parotidectomies for cutaneous melanoma. Am J Surg 168 (1994) 400-403
90. McKean M.E., Lee K., and McGregor I.A. The distribution of lymph nodes in and around the parotid gland: an anatomical study. Br J Surg 38 (1985) 1-5
91. Wells K.E., Stadelmann W.K., Rapaport D.P., et al. Parotid selective lymphadenectomy in malignant melanoma. Ann Plast Surg 43 (1999) 1-6
92. Stadelmann W.K., McMasters K.M., Digenis A.G., et al. Cutaneous melanoma of the head and neck: new advances in evaluation and treatment. Plast Reconstr Surg 105 6 (2000) 2105-2126
93. Rousseau Jr. D.L., Ross M.I., Johnson M.M., et al. Revised Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10 (2003) 569-574
94. Vuylsteke R.J.C.L.M., van Leeuwen P.A.M., Muller M.G.S., et al. Clinical outcome of stage I/II melanoma patients after selective lymph node dissection: long-term follow-up results. J Clin Oncol 21 (2003) 1057-1065
95. Elias N., Tanabe K.K., Sober A.J., et al. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary?. Arch Surg 139 (2004) 400-404
96. Chao C., Wong S.L., and Ross M.I. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 184 (2002) 520-524
97. Sigletary S.E., Greene F.L., and Sobin L.H. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 90 (2003) 2740-2741
98. Schuchter L.M. Review of the 2001 AJCC staging system for cutaneous malignant melanoma. Curr Oncol Rep 3 (2001) 332-337
99. van Akkooi A.C., de Wilt J.H., Verhoef C., et al. Clinical relevance of melanoma micro metastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 17 (2006) 1578-1585
100. Scheri R.P., Essner R., Turner R.R., et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14 (2007) 2861-2866
101. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 (1999) 976-983
102. Zogakis T.G., Essner R., Wang H.-J., et al. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol 14 (2007) 1604-1611
103. Gershenwald J.E., Colome M.I., Lee F.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16 (1998) 2253-2260
104. Leong S.P., Thelmo M.C., Kim R.P., et al. Delayed harvesting of sentinel lymph nodes after previous wide local excision of extremity melanoma. Ann Surg Oncol 10 2 (2003) 196-200
105. Kelemen P.R., Essner R., Foshag L.J., et al. Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma. J Am Coll Surg 189 (1999) 247-252
106. Wells KE, Joseph E, Ross M, et al. Lymphatic mapping for melanoma before and after wide local excision: 4th World Conference on Melanoma. Sydney, Australia: Melanoma Research, 1997:S105.
107. Miner T.J., Shriver C.D., Flicek P.R., et al. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. Ann Surg Oncol 6 (1999) 75-82